



SumiSaujana Group Bhd

Business Momentum Holds as Geopolitical Risks Contained

Despite geopolitical noise, the Group is executing a high-conviction pivot via the Pengerang contract mobilization, a North American toll-manufacturing JV, and a 2QFY26 entry into high-margin bio-based chemicals. This strategic scaling, supported by the new Puncak Alam complex and a group-wide cost-rationalization exercise, is designed to optimize operational efficiency and drive significant long-term margin expansion. We raise our FY26E earnings by 21% while lowering FY27E earnings by 35%. Subsequently, we raise TP by 20% to RM0.132, based on a revised FY26E EPS of 0.77 sen ascribed to a 17.2x (previously 17.5x) PE multiple. Upgrade to BUY.

We attended SumiSaujana's recent post-results company update and the key operational insights and outlook takeaways are summarized below:

- FY25 results recap.** SUMI's revenue rose c.16% YoY to c.RM184m from strong production output mitigated by the stronger Ringgit. However, gross profit margin narrowed by 4 pts due to an unfavourable product mix and lower selling price. Consequently, PBT declined 62% to c.RM13m from c.RM21m in FY24, mainly dragged by one-off listing expenses and net forex losses of RM1.4m and RM3.6m, respectively. Management also highlighted that about 60% of the Group's earnings are USD-denominated.
- Utilisation and operating trends.** SUMI operated at c.40% utilisation of its total production capacity of 32,500 tonnes, across five reactors and three hybrid reactor tanks. The manufacturing segment accounted for 60%–70% of group revenue, with the balance contributed by trading and support services. We estimate output volume grew by c.17%; however, this did not translate into stronger topline growth due to the appreciation of the Ringgit and lower average selling prices, as management pursued market share expansion.
- Resilience amid Middle East Conflict.** Despite the ongoing Middle East conflict, management assured business runs as usual, as we estimate c.80% of Group revenue is encapsulated within the Asia Pacific and American regions. While shipping disruptions have caused localized logistical delays, Middle East order flow remains intact; management views these as timing-based bottlenecks rather than a loss of demand. Sustained supply commitments from core customers in Kuwait and Oman support a clear revenue catch-up narrative once logistical channels normalize.
- Progress Updates.** Management is aggressively executing its capacity expansion, with several key facilities and projects nearing full operational status:
 - Puncak Alam Integrated Complex:** The newly acquired warehouse facility (>100,000 sq. ft.) successfully commenced utilization in 3QFY25. Full renovation of the corporate office and warehouse are on track for completion and occupancy by early-April 2026.
 - Pengerang Mobilization:** Operations for the 3-year specialized supply contract with Pengerang Refining Company Sdn Bhd (PRCSB) are scheduled to commence in April–May 2026. This contract involves the supply of Di-tert-butyl Polysulfide (TBPS) and Ethyl Mercaptan (EM), along with technical in-situ sulfiding services.

Company Update

BUY (↑)


research@mersec.com.my

Monday, March 16, 2026

Price: RM 0.110

Target Price: RM 0.132 (↑)

Share Price Performance



Business Overview

SUMI Group Bhd manufacture specialty chemicals for the oil & gas industry's upstream, midstream and downstream sectors. Their products, ranging from drilling fluid and production chemicals to refinery additives. Listed in the ACE Market under Oil & Gas.

Return Information

KLCI (pts)	1,698.85
YTD KLCI chg.	1.1%
YTD Stock Price chg.	(4.3%)

Price Performance	1M	3M	12M
Absolute (%)	0.0%	22.2%	n/a
Relative to KLCI (%)	2.3%	18.5%	n/a

Stock Information

Market Cap (RM m)	158.8
Issued Shares (m)	1,443.6
52-week High (RM)	0.21
52-week Low (RM)	0.08
Est. Free Float (%)	31.2
Beta vs FBM KLCI	N.A
3-month Avg Vol. (m)	1,742,252
Shariah Compliant	Yes
Bloomberg Ticker	SUMI MK EQUITY

Top 3 Shareholders

Shareholder	%
Atreon Holdings Bhd	65.0
Norazlam bin Norbi	1.7
Toh Chee Seng	1.7

FY Mar (RM m)	FY25A	FY26E	FY27E
Revenue	183.6	181.9	189.2
EBITDA	17.2	24.0	25.3
PBT	11.7	14.0	14.0
Net Profit	12.8	15.6	15.3
Core Net Profit	8.3	11.1	11.7
Consensus Net Profit	8.3	11.1	11.7
Earnings Revision (%)		12.2	29.0
Core EPS (sen)		21.8%	-34.5%
Core EPS Growth (%)	0.58	0.77	0.81
Net DPS (sen)	-	0.23	0.24
Net Div. Yield (%)	-	2.09	2.20
BV Per Share (sen)	11.66	12.20	12.76
P/E (x)	19.0	14.3	13.6
PBV (x)	0.9	0.9	0.9
ROE (%)	5%	6%	6%



- c) **China Bio-Polyol MOU:** Under the strategic partnership with CoolisT Group, the supply of specialty additives and the commercialization of renewable vegetable oil-based bio-polyols are targeted to begin in Q2 2026.
- d) **Indonesia WSA Project:** SUMI is transitioning into a Technology Partner for the Wet Gas Sulphuric Acid (WSA) facility project in collaboration with PT Kilang Pertamina Internasional, Topsoe A/S, and SPCI HELM. The next phase, under a Build-Own-Operate-Transfer (BOOT) model, is expected to kick off in Q2 2026.
- e) **North America Expansion:** The Group is advancing its toll-manufacturing strategy in the U.S. market, leveraging its recently granted USPTO patents for sand agglomeration chemicals to localize production and mitigate shipping overheads by 1HFY26.

Earnings estimates revised. Raise our FY26E earnings by 21%. This reflects i) the absence of one-off listing expenses, ii) lower forex volatility, as management guided for a stable USD/MYR outlook, iii) a higher effective tax rate assumption of 29% (from 24% previously), in line with management guidance, and iv) a 2 pts increase in our output growth assumption to 3%, as we expect stronger contributions from the Asia-Pacific and American markets. These positives are partly offset by lower selling prices and the normalisation of the Ringgit, which together reduce topline by c.15%.

For FY27E, we cut earnings by 35%, mainly due to lower assumed selling prices and a normalised Ringgit, although this is partly cushioned by unchanged output growth of 4%.

We maintained our 30% dividend payout assumption for FY26E–FY27E, supported by the absence of post-listing expenses and a more stable MYR/USD environment.

Valuation. Based on our revised FY26E EPS of 0.77 sen (previously 0.63 sen) and a lower target PER of 17.2x (from 17.5x), which implies a 50% discount to the its peers 10-year global average, we derive a new TP of RM0.132 (previously RM0.110). Undemanding valuations (as FY26E P/BV < 1.0x), we upgrade the stock to **BUY**.

Outlook. Despite evolving U.S. trade policies and geopolitical volatility in the Middle East, management maintains an optimistic outlook for FY26, supported by resilient global drilling activity and the full recognition of one-off listing expenses in FY25. The Group is aggressively executing its next growth phase by scaling North American toll-manufacturing operations and pursuing strategic collaborations to deepen its Middle East footprint, while simultaneously diversifying into bio-based industrial chemicals via its MPOB-licensed and CoolisT partnerships slated for 2Q26. These initiatives are being complemented by an internal cost-rationalization exercise and the centralization of operations at the new Puncak Alam facility, which are expected to optimize the Group's cost structure and drive long-term margin expansion.

Investment case. We maintain a positive long-term outlook on SUMI, underpinned by its defensible market position and strategic diversification. The Group's core strength lies in its robust institutional ties, with its top four global O&G clients—led by Petronas—accounting for 78% of revenue (c.80% revenue comes from Asia-Pacific/Americas). Beyond its legacy portfolio, SUMI is pivoting toward high-growth industrial applications, specifically bio-based lubricants and transformer oils. This expansion is supported by a dual-track strategy: (i) geographical scaling, with new production facilities in North America and the Middle East slated for execution by 1HFY26, and (ii) innovation-led growth via its MPOB partnership, leveraging palm-based polyols to capture the accelerating demand for sustainable biochemicals.

Risks to our recommendation include: (i) Dependence on key customers, (ii) Foreign currency exposure, (iii) Raw materials input cost fluctuation.

Key Financial Data

Income Statement						Financial Data & Ratios					
FY Dec (RM m)	2024A	2025A	2026E	2027E	2028E	FY Dec	2024A	2025A	2026E	2027E	2028E
Revenue	158.6	183.6	181.9	189.2	196.8	Growth					
EBITDA	26.3	17.2	24.0	25.3	26.6	Turnover	-20.2%	15.8%	-0.9%	4.0%	4.0%
Depreciation & Amortz	(5.4)	(5.4)	(10.0)	(11.2)	(10.4)	EBITDA	-44.2%	-34.8%	39.9%	5.2%	5.5%
Operating Profit	20.9	11.7	14.0	14.0	16.3	Operating Profit	-50.8%	-43.8%	19.3%	0.2%	16.1%
Interest Inc/(Exp)	(0.4)	1.0	1.6	1.3	1.8	PBT	-50.3%	-37.8%	22.1%	-1.8%	18.3%
Profit Before Tax	20.5	12.8	15.6	15.3	18.1	Core Net Profit	-44.0%	-51.3%	32.9%	5.1%	18.3%
Taxation	(3.4)	(4.4)	(4.5)	(3.7)	(4.4)	Profitability					
Net Profit	17.1	8.3	11.1	11.7	13.8	Gross Profit Margin	33.5%	29.2%	30.0%	30.0%	30.0%
PATAMI	17.1	8.3	11.1	11.7	13.8	EBITDA Margin	16.6%	9.3%	13.2%	13.3%	13.5%
Balance Sheet						Operating Margin	13.2%	6.4%	7.7%	7.4%	8.3%
Fixed Assets	34.3	56.3	96.1	92.9	90.6	PBT Margin	13.0%	7.0%	8.6%	8.1%	9.2%
Intangible Assets	0.0	0.2	0.2	0.2	0.2	Core Net Margin	10.8%	4.5%	6.1%	6.2%	7.0%
ROU Assets	2.1	10.3	10.3	10.3	10.3	Effective Tax Rate	16.6%	34.8%	29.0%	24.0%	24.0%
Other Fixed Assets	0.0	0.1	0.1	0.1	0.1	ROA	100.2%	5.0%	6.3%	6.3%	7.1%
Inventories	25.5	25.8	25.4	26.5	27.5	ROE	12.8%	3.4%	4.5%	4.5%	5.1%
Receivables	36.2	65.7	65.0	67.6	70.3	Leverage					
Other Current Assets	37.5	100.1	65.2	75.8	86.2	Debt/Asset (x)	0.2	0.1	0.1	0.1	0.1
Cash	31.3	95.3	60.4	71.0	81.4	Debt/Equity (x)	1.3	0.2	0.2	0.1	0.1
Total Assets	133.5	247.8	248.7	257.5	267.6	Net (Cash)/Debt	(8.9)	(63.6)	(32.9)	(45.9)	(58.6)
Payables	18.9	39.7	37.8	39.4	40.9	Net Debt/Equity (x)	(0.5)	(0.4)	(0.2)	(0.2)	(0.3)
ST Borrowings	12.7	22.2	21.2	22.0	22.9	Valuations					
Other ST Liability	65.5	88.1	42.3	39.7	42.8	Core EPS (sen)	1.2	0.6	0.8	0.8	1.0
LT Borrowings	9.7	9.5	6.3	3.2	0.0	NDPS (sen)	0.0	0.0	0.2	0.2	0.3
Other LT Liability	5.9	5.4	5.4	5.4	5.4	BV/sh (RM)	0.01	0.12	0.12	0.13	0.13
Net Assets	17.1	168.3	176.1	184.2	193.9	PER (x)	9.3	19.0	14.3	13.6	11.5
Shareholders' Equity	17.1	168.3	176.1	184.2	193.9	Div. Yield (%)	0.0	0.0	2.1	2.2	2.6
Minority Interests	0.0	0.0	0.0	0.0	0.0	PBV (x)	9.3	0.9	0.9	0.9	0.8
Total Equity	17.1	168.3	176.1	184.2	193.9						
Cashflow Statement											
FY Mar (RM m)											
Operating CF	32.2	11.2	20.3	20.8	22.0						
Investing CF	(6.7)	(28.6)	(43.8)	(3.5)	(4.2)						
Financing CF	(21.0)	79.9	(6.5)	(6.7)	(7.3)						
Change In Cash	4.5	62.5	(30.0)	10.6	10.4						
Free CF	25.9	(15.1)	(23.5)	17.3	17.8						

Source: Mercury Securities, Company



Disclaimer & Disclosure of Conflict of Interest

This report has been prepared by research analyst(s) of Mercury Securities pursuant to the Research Incentive Program under Bursa Research Incentive Scheme Plus (“Bursa RISE+”) administered by Bursa Malaysia Berhad. This report has been produced independent of any influence from Bursa Malaysia Berhad or the subject company. Bursa Malaysia Berhad and its group of companies disclaim any and all liability, howsoever arising, out of or in relation to the administration of Bursa Research Incentive Program and/or this report. This research report can also be found in the Bursa Marketplace or via the link: <https://www.bursamarketplace.com/mkt/tools/research>.

The information contained in this report is based on data obtained from data and sources believed to be reliable at the time of issue of this report. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, are made as to the accuracy, adequacy, completeness or reliability of the information or opinions in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as “believe”, “estimate”, “intend” and “expect” and statements that an event or result “may”, “will” or “might” occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to Mercury Securities Sdn Bhd. (“Mercury Securities”) and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. Mercury Securities expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

Accordingly, neither Mercury Securities nor any of its holding company, related companies, directors, employees, agents and/or associates nor person connected to it accept any liability whatsoever for any direct, indirect, or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the information or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. Mercury Securities has no obligation to update its opinion or the information in this report.

This report does not have regard to the specific investment objectives, financial situation and particular needs of any specific person. Accordingly, investors are advised to make their own independent evaluation of the information contained in this report and seek advice from, amongst others, tax, accounting, financial planner, legal or other business professionals regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represents a personal recommendation to you. This report is not intended, and should not under no circumstances be considered as an offer to sell or a solicitation of any offer or a solicitation or expression of views to influence any one to buy or sell the securities referred to herein or any related financial instruments.

Mercury Securities and its holding company, related companies, directors, employees, agents, associates and/or person connected with it may, from time to time, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or be materially interested in any securities mentioned herein or any securities related thereto, and may further act as market maker or have assumed underwriting commitment or deal with such securities and provide advisory, investment, share margin facility or other services for or do business with any companies or entities mentioned in this report. In reviewing the report, investors should be aware that any or all of the foregoing among other things, may give rise to real or potential conflict of interests and should exercise their own judgement before making any investment decisions.

This research report is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this report, unless specifically indicated otherwise, are under copyright to Mercury Securities. This research report and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted, or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.

This report may provide the addresses of, or contain hyperlinks to websites. Mercury Securities takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to Mercury Securities own website material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or Mercury Securities’ website shall be at your own risk.

This report is not directed to or intended for distribution or publication outside Malaysia. If you are outside Malaysia, you should have regard to the laws of the jurisdiction in which you are located.

The views expressed in this research report accurately reflect the analyst’s personal views about any and all of the subject securities or issuers; and no part of the research analyst’s compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.



Recommendation Rating

Mercury Securities maintains a list of stock coverage. Stock can be added or dropped subject to needs with or without notice. Hence, the recommendation rating only applicable to stocks under the list. Stocks out of the coverage list will not carry recommendation rating as the analyst may not follow the stocks adequately.

Mercury Securities has the following recommendation rating:

BUY	Stock's total return is expected to be +10% or better over the next 12 months (including dividend yield)
HOLD	Stock's total return is expected to be within +10% or -10% over the next 12 months (including dividend yield)
SELL	Stock's total return is expected to be -10% or worse over the next 12 months (including dividend yield)

Published & Printed By:

MERCURY SECURITIES SDN BHD
Registration No. 198401000672 (113193-W)
L-7-2, No 2, Jalan Solaris, Solaris Mont' Kiara, 50480 Kuala Lumpur
Telephone: (603) - 6203 7227
Website: www.mercurysecurities.com.my
Email: mercurykl@mersec.com.my